What is HC Wainwright’s Forecast for CRDL FY2024 Earnings?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Equities researchers at HC Wainwright lifted their FY2024 EPS estimates for Cardiol Therapeutics in a research note issued to investors on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings per share of ($0.38) for the year, up from their previous estimate of ($0.44). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Cardiol Therapeutics’ Q4 2024 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

Cardiol Therapeutics Trading Up 1.0 %

Shares of NASDAQ:CRDL opened at $1.58 on Friday. The company has a market capitalization of $128.52 million, a P/E ratio of -4.04 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49. The business’s 50 day simple moving average is $1.95 and its 200 day simple moving average is $2.08. Cardiol Therapeutics has a 1 year low of $0.79 and a 1 year high of $3.12.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC acquired a new stake in Cardiol Therapeutics during the third quarter worth about $27,000. Townsquare Capital LLC acquired a new stake in shares of Cardiol Therapeutics during the 3rd quarter worth approximately $27,000. Jane Street Group LLC acquired a new stake in shares of Cardiol Therapeutics during the 3rd quarter worth approximately $29,000. Lion Street Advisors LLC increased its stake in Cardiol Therapeutics by 7.9% in the third quarter. Lion Street Advisors LLC now owns 273,281 shares of the company’s stock valued at $544,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new position in Cardiol Therapeutics during the second quarter valued at approximately $59,000. Institutional investors and hedge funds own 12.49% of the company’s stock.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.